Last reviewed · How we verify
Other Anti-Retroviral Therapy
At a glance
| Generic name | Other Anti-Retroviral Therapy |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- HIV Self-testing for Partners of HIV-uninfected Postpartum Women (NA)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Getting to Zero Among HHI MSM in the American South (NA)
- Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants
- Choice-Based Support for Adults Starting or Restarting Antiretroviral Therapy in Cape Town, South Africa (NA)
- Immediate ART in Subjects With Opportunistic Diseases (NA)
- Structured Peer-delivered ART and Reentry Community Strategy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other Anti-Retroviral Therapy CI brief — competitive landscape report
- Other Anti-Retroviral Therapy updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI